These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 10578457)

  • 1. Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia.
    Schulz SC; Camlin KL; Berry SA; Jesberger JA
    Biol Psychiatry; 1999 Nov; 46(10):1429-35. PubMed ID: 10578457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study.
    Zanarini MC; Frankenburg FR
    J Clin Psychiatry; 2001 Nov; 62(11):849-54. PubMed ID: 11775043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Tolerability of Asenapine Compared with Olanzapine in Borderline Personality Disorder: An Open-Label Randomized Controlled Trial.
    Bozzatello P; Rocca P; Uscinska M; Bellino S
    CNS Drugs; 2017 Sep; 31(9):809-819. PubMed ID: 28741044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Open-label study of atypical neuroleptic quetiapine for treatment of borderline personality disorder: impulsivity as main target.
    Villeneuve E; Lemelin S
    J Clin Psychiatry; 2005 Oct; 66(10):1298-303. PubMed ID: 16259544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Open-label treatment with olanzapine for patients with borderline personality disorder.
    Zanarini MC; Schulz SC; Detke H; Zhao F; Lin D; Pritchard M; Deberdt W; Fitzmaurice G; Corya S
    J Clin Psychopharmacol; 2012 Jun; 32(3):398-402. PubMed ID: 22544004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An open-label study of the treatment efficacy of olanzapine for Tourette's disorder.
    Budman CL; Gayer A; Lesser M; Shi Q; Bruun RD
    J Clin Psychiatry; 2001 Apr; 62(4):290-4. PubMed ID: 11379844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Yi-gan san for the treatment of borderline personality disorder: an open-label study.
    Miyaoka T; Furuya M; Yasuda H; Hayashia M; Inagaki T; Horiguchi J
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Jan; 32(1):150-4. PubMed ID: 17765378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A dose comparison of olanzapine for the treatment of borderline personality disorder: a 12-week randomized, double-blind, placebo-controlled study.
    Zanarini MC; Schulz SC; Detke HC; Tanaka Y; Zhao F; Lin D; Deberdt W; Kryzhanovskaya L; Corya S
    J Clin Psychiatry; 2011 Oct; 72(10):1353-62. PubMed ID: 21535995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Olanzapine versus haloperidol in the management of borderline personality disorder: a randomized double-blind trial.
    Shafti SS; Shahveisi B
    J Clin Psychopharmacol; 2010 Feb; 30(1):44-7. PubMed ID: 20075647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of phenelzine and haloperidol in borderline personality disorder.
    Soloff PH; Cornelius J; George A; Nathan S; Perel JM; Ulrich RF
    Arch Gen Psychiatry; 1993 May; 50(5):377-85. PubMed ID: 8489326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of quetiapine in the treatment of borderline personality disorder: A pilot study.
    Bellino S; Paradiso E; Bogetto F
    J Clin Psychiatry; 2006 Jul; 67(7):1042-6. PubMed ID: 16889446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Olanzapine versus placebo in the treatment of borderline personality disorder.
    Bogenschutz MP; George Nurnberg H
    J Clin Psychiatry; 2004 Jan; 65(1):104-9. PubMed ID: 14744178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Olanzapine for the treatment of borderline personality disorder: variable dose 12-week randomised double-blind placebo-controlled study.
    Schulz SC; Zanarini MC; Bateman A; Bohus M; Detke HC; Trzaskoma Q; Tanaka Y; Lin D; Deberdt W; Corya S
    Br J Psychiatry; 2008 Dec; 193(6):485-92. PubMed ID: 19043153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of quetiapine for impulsivity and affective symptoms in borderline personality disorder.
    Van den Eynde F; Senturk V; Naudts K; Vogels C; Bernagie K; Thas O; van Heeringen C; Audenaert K
    J Clin Psychopharmacol; 2008 Apr; 28(2):147-55. PubMed ID: 18344724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quetiapine in patients with borderline personality disorder: an open-label trial.
    Adityanjee ; Romine A; Brown E; Thuras P; Lee S; Schulz SC
    Ann Clin Psychiatry; 2008; 20(4):219-26. PubMed ID: 19034754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of aripiprazole augmentation in sertraline-resistant patients with borderline personality disorder.
    Bellino S; Paradiso E; Bogetto F
    Psychiatry Res; 2008 Nov; 161(2):206-12. PubMed ID: 18848360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose clozapine in acute and continuation treatment of severe borderline personality disorder.
    Benedetti F; Sforzini L; Colombo C; Maffei C; Smeraldi E
    J Clin Psychiatry; 1998 Mar; 59(3):103-7. PubMed ID: 9541151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of antipsychotic drug treatment on prolactin concentrations in elderly patients.
    Kinon BJ; Stauffer VL; McGuire HC; Kaiser CJ; Dickson RA; Kennedy JS
    J Am Med Dir Assoc; 2003; 4(4):189-94. PubMed ID: 12837139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose olanzapine for self-mutilation behavior in patients with borderline personality disorder.
    Hough DW
    J Clin Psychiatry; 2001 Apr; 62(4):296-7. PubMed ID: 11379847
    [No Abstract]   [Full Text] [Related]  

  • 20. Olanzapine plus dialectical behavior therapy for women with high irritability who meet criteria for borderline personality disorder: a double-blind, placebo-controlled pilot study.
    Linehan MM; McDavid JD; Brown MZ; Sayrs JH; Gallop RJ
    J Clin Psychiatry; 2008 Jun; 69(6):999-1005. PubMed ID: 18466045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.